1677.1 – Pharmacy Diabetes Screening Trial

The Sixth Community Pharmacy Agreement provided funding to support a Pharmacy Trial Program (PTP), which seeks to improve clinical outcomes for patients and/or utilise the full scope of a pharmacists role in delivering primary health care services.

The outcomes of all PTP Trials will undergo an independent Health Technology Assessment (HTA) to determine the effectiveness and cost-effectiveness of the trial intervention and inform decisions about any broader rollout. A decision to fund any future programs would be a matter for Government.

Information on the PTP is available on the Department of Health website.

The Pharmacy Diabetes Screening Trial compared three different pharmacy-based screening models:

1. Risk assessment using a validated tool (AUSDRISK) alone (group A)
2. AUSDRISK followed by point-of-care glycated haemoglobin (group B)
3. AUSDRISK followed by point-of-care blood glucose testing (group C)

Type: Investigative

Diabetes mellitus is a chronic disorder that reduces the body’s ability to produce and/or use insulin (a hormone produced by the pancreas to regulate blood sugar levels). This results in high blood sugar levels, which lead to serious complications such as stroke; diabetes-related eye disease such as diabetic retinopathy; heart disease; high blood pressure; kidney disease; vascular disease; nerve damage; and foot problems.

• PASC consultation: Not applicable
• MSAC consultation: Closed Friday 16 February 2024

• PASC meeting: Expedited – Bypassed PASC
• ESC meeting: 15 to 16 February 2024
• MSAC meeting: -